Voyager Therapeutics (VYGR) Tops Q2 EPS by 23c

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.18), $0.23 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $29.58 million versus the consensus estimate of $9.51 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• HII targets 15% shipbuilding throughput increase for U.S. Navy in 2026
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral